Under construction – not a live service
Sign in
Not yet taking people in SwitzerlandPhase 1/2

A new PET scan tracer, [18F]FAPI-74, for imaging several cancers and sarcoidosis

Tests the [18F]FAPI-74 PET scan tracer in adults with suspected or confirmed disease.

Key facts

Who runs it
Martin Huellner
Where
Baden, Geneva, Genolier, Lucerne, and Zurich, SwitzerlandSee the 5 sites
Trial code
Registry title
FAPI PET Imaging - An Exploratory Study
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
770 people, planned
Started
Aug 2026
Expected to end
Sept 2029
Type of study
Interventional
Treatments tested
  • [18F]FAPI-74 PET/CT
Record updated
15 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a confirmed or suspected cancer or non-cancer disease such as sarcoidosis. They get one injection of a new tracer and one PET scan.

Age
18 years or older
Sex
All sexes can join
Disease stage
A confirmed or suspected diagnosis, or a return of the disease, of one of the listed cancer or non-cancer conditions

Main reasons for not taking part

  • Severe fear of enclosed spaces that prevents a PET scan
  • Cannot lie still during the PET/MR scan
  • Pregnant or breastfeeding
  • Earlier allergic reaction to a radiotracer
  • Metal implants or devices not safe for MRI (for those having a PET/MR scan)

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Written informed consent obtained and documented by the participant's signature
  • Age ≥18 years at the time of consent
  • Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol
  • Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT/MRI) to allow comparative evaluation

Who cannot take part

  • Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy
  • Previous hypersensitivity reactions to radiotracer administration
  • Participants scheduled for PET/MR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies
  • Severe claustrophobia that would preclude PET imaging
  • Inability to remain still for the duration of the PET/MR examination
  • Inability to understand the study information, for example due to language barriers
  • Subjects incapable of judgment (e.g. individuals under legal or medical incapacity)

Where in Switzerland

  • Kantonsspital BadenBaden, SwitzerlandContact: Irene Burger, Prof. Dr. med.No longer taking part
  • Hôpitaux Universitaires de Genève (HUG)Geneva, SwitzerlandContact: Ismini Mainta, Dr. med.No longer taking part
  • Clinique de GenolierGenolier, SwitzerlandContact: Antoine Leimgruber, Dr. med.No longer taking part
  • Luzerner KantonsspitalLucerne, SwitzerlandContact: Klaus Strobel, Prof. Dr. med.No longer taking part
  • Department for Nuclear Medicine, University Hospital ZurichZurich, SwitzerlandContact: Patrick PerronNo longer taking part

About the trial

What the trial wants to find out

This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis.

Read full original descriptionShow less

[18F]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well.

People who join this study will get one injection of the tracer into a vein, then have one PET/CT or PET/MR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed.

The study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.

The group in the trial

  • [18F]FAPI-74 PET ImagingTreatment being tested

    Participants receive a single intravenous injection of approximately 250 MBq \[18F\]FAPI-74 (fluorine-18 labelled FAP-targeted PET radiotracer), followed by one PET/CT or PET/MR scan performed 45-60 minutes post-injection. For PET/CT acquisitions, a low-dose CT is performed for attenuation correction and anatomical localization. No therapeutic intervention, randomization, or repeat tracer administration is involved. Uptake and diagnostic image quality are assessed qualitatively by a nuclear medicine physician from the local study team. Findings are compared with each participant's own previously acquired standard-of-care imaging (e.g., FDG-PET/CT, PSMA-PET/CT, CT, or MRI), which serves as the reference standard rather than a concurrent study arm. Total participation time is approximately 2 hours on a single study day.

    Treatment: [18F]FAPI-74 PET/CT

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
FAPI PET Imaging - a Multicentric Exploratory Evaluation
Plain-language title
A new PET scan tracer, [18F]FAPI-74, for imaging several cancers and sarcoidosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
15 July 2026